1214271-89-2

Upstream product

• 555-21-5 4-Nitrophenylacetonitrile 
• 780763-92-0 [4,6-dichloro-2-(4-nitrobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 39695-96-0 2-(4-nitrophenyl)ethanimidamide hydrochloride 
• 780763-91-9 [4,6-dihydroxy-2-(4-nitrobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 1214271-93-8 methyl [4,6-bis([(2H)6]dimethylamino)-2-(4-nitrobenzyl)pyrimidin-5-yl]acetate 
• 1214271-94-9 methyl [2-(4-aminobenzyl)-4,6-bis([(2H)6]dimethyl-amino)pyrimidin-5-yl]acetate 
• 1214271-95-0 methyl [4,6-bis([(2H)6]dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetate 

Relevant academic research and scientific papers

ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

Provided herein are 2H- and 13C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical compositions and methods using the 2H- and 13C-enriched compounds, useful for treating CRTH2-related diseases or disorders such as, for example, asthma, allergic rhinitis, atopic dermatitis, allergic conjuvatitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.